drugset / Trial / NCT00736541

N-acetylcysteine in Liver Transplantation

NCT00736541

Completed 100 enrolled Ibtesam Hilmi
RandomizedParallel-groupQuadruple-blindPrevention

Summary

N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients who undergo orthotopic liver transplantation (OLT) have a high incidence of post-operative renal dysfunction. The most common etiology of post-operative renal dysfunction is related to high levels of toxic free radicals. Free radicals may contribute to primary liver graft failure or delayed liver graft function. Specific Aims \& Objectives: The primary objective of this study is to evaluate the efficacy of NAC in improving liver graft performance and lowering the incidence of post-operative renal dysfunction. The secondary objectives are to investigate the effect of NAC on endogenous glutathione body stores and its effect on FK506 induced toxicity.

Timeline

Start
2004-07
Primary completion
2007-04
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 70 mg/kg Intravenous

Indications